Reported Consolidated quarterly numbers for GlaxoSmithKline Pharmaceuticals are:Net Sales at Rs 814.65 crore in June 2024 up 6.96% from Rs. 761.66 crore in June 2023.
Quarterly Net Profit at Rs. 182.33 crore in June 2024 up 37.87% from Rs. 132.25 crore in June 2023.
EBITDA stands at Rs. 266.18 crore in June 2024 up 47.62% from Rs. 180.32 crore in June 2023.
GlaxoSmithKline EPS has increased to Rs. 10.76 in June 2024 from Rs. 7.04 in June 2023.
| GlaxoSmithKline shares closed at 2,763.95 on August 05, 2024 (NSE) and has given 12.90% returns over the last 6 months and 97.55% over the last 12 months. |
| GlaxoSmithKline Pharmaceuticals | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Jun'24 | Mar'24 | Jun'23 | | Net Sales/Income from operations | 814.65 | 929.80 | 761.66 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 814.65 | 929.80 | 761.66 | | EXPENDITURE | | Consumption of Raw Materials | 138.23 | 204.60 | 158.41 | | Purchase of Traded Goods | 172.74 | 255.74 | 174.20 | | Increase/Decrease in Stocks | -15.70 | -93.21 | -36.49 | | Power & Fuel | -- | -- | -- | | Employees Cost | 151.28 | 172.83 | 165.00 | | Depreciation | 16.41 | 18.10 | 16.36 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 137.56 | 132.58 | 156.66 | | P/L Before Other Inc., Int., Excpt. Items & Tax | 214.13 | 239.16 | 127.52 | | Other Income | 35.64 | 29.83 | 36.44 | | P/L Before Int., Excpt. Items & Tax | 249.77 | 268.99 | 163.96 | | Interest | 0.37 | 0.77 | 0.28 | | P/L Before Exceptional Items & Tax | 249.40 | 268.22 | 163.68 | | Exceptional Items | -- | 2.40 | 17.30 | | P/L Before Tax | 249.40 | 270.62 | 180.98 | | Tax | 67.07 | 76.14 | 48.73 | | P/L After Tax from Ordinary Activities | 182.33 | 194.48 | 132.25 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 182.33 | 194.48 | 132.25 | | Minority Interest | -- | -- | -- | | Share Of P/L Of Associates | -- | -- | -- | | Net P/L After M.I & Associates | 182.33 | 194.48 | 132.25 | | Equity Share Capital | 169.41 | 169.41 | 169.41 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 10.76 | 11.37 | 7.04 | | Diluted EPS | 10.76 | 11.48 | 7.81 | | EPS After Extra Ordinary | | Basic EPS | 10.76 | 11.37 | 7.04 | | Diluted EPS | 10.76 | 11.48 | 7.81 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
